930 related articles for article (PubMed ID: 25411122)
1. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
Xun Y; Yang H; Kaminska B; You H
J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
[TBL] [Abstract][Full Text] [Related]
3. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
4. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell immunotherapy for malignant gliomas.
Luptrawan A; Liu G; Yu JS
Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
7. Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of T cell responses.
Salem ML
Immunol Lett; 2011 Jun; 137(1-2):9-14. PubMed ID: 21352854
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
10. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
12. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
13. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
14. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
15. Immunobiology and immunotherapeutic targeting of glioma stem cells.
Madany M; Thomas TM; Edwards L; Yu JS
Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
[TBL] [Abstract][Full Text] [Related]
16. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
Mikulandra M; Pavelic J; Glavan TM
Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
[TBL] [Abstract][Full Text] [Related]
17. Biological Response Modifier in Cancer Immunotherapy.
Liu R; Luo F; Liu X; Wang L; Yang J; Deng Y; Huang E; Qian J; Lu Z; Jiang X; Zhang D; Chu Y
Adv Exp Med Biol; 2016; 909():69-138. PubMed ID: 27240457
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors: cost or benefit for cancer?
Matijevic T; Pavelic J
Curr Pharm Des; 2010; 16(9):1081-90. PubMed ID: 20030618
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
Ohadian Moghadam S; Nowroozi MR
Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
